Robert Schreiber
Robert Schreiber
Washington University School of Medicine
Bestätigte E-Mail-Adresse bei
TitelZitiert vonJahr
How cells respond to interferons
GR Stark, IM Kerr, BRG Williams, RH Silverman, RD Schreiber
Annual review of biochemistry 67 (1), 227-264, 1998
Bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death
D Hockenbery, G Nuñez, C Milliman, RD Schreiber, SJ Korsmeyer
Nature 348 (6299), 334, 1990
Cancer immunoediting: from immunosurveillance to tumor escape
GP Dunn, AT Bruce, H Ikeda, LJ Old, RD Schreiber
Nature immunology 3 (11), 991, 2002
Cancer immunoediting: integrating immunity’s roles in cancer suppression and promotion
RD Schreiber, LJ Old, MJ Smyth
Science 331 (6024), 1565-1570, 2011
IFNγ and lymphocytes prevent primary tumour development and shape tumour immunogenicity
V Shankaran, H Ikeda, AT Bruce, JM White, PE Swanson, LJ Old, ...
Nature 410 (6832), 1107, 2001
The immunobiology of cancer immunosurveillance and immunoediting
GP Dunn, LJ Old, RD Schreiber
Immunity 21 (2), 137-148, 2004
The three Es of cancer immunoediting
GP Dunn, LJ Old, RD Schreiber
Annu. Rev. Immunol. 22, 329-360, 2004
Targeted disruption of the Stat1 gene in mice reveals unexpected physiologic specificity in the JAK–STAT signaling pathway
MA Meraz, JM White, KCF Sheehan, EA Bach, SJ Rodig, AS Dighe, ...
Cell 84 (3), 431-442, 1996
The molecular cell biology of interferon-gamma and its receptor
MA Farrar, RD Schreiber
Annual review of immunology 11 (1), 571-611, 1993
Demonstration of an interferon γ-dependent tumor surveillance system in immunocompetent mice
DH Kaplan, V Shankaran, AS Dighe, E Stockert, M Aguet, LJ Old, ...
Proceedings of the national academy of sciences 95 (13), 7556-7561, 1998
Neoantigens in cancer immunotherapy
TN Schumacher, RD Schreiber
Science 348 (6230), 69-74, 2015
Natural innate and adaptive immunity to cancer
MD Vesely, MH Kershaw, RD Schreiber, MJ Smyth
Annual review of immunology 29, 235-271, 2011
Interferons, immunity and cancer immunoediting
GP Dunn, CM Koebel, RD Schreiber
Nature Reviews Immunology 6 (11), 836, 2006
Intracellular inactivation of the hepatitis B virus by cytotoxic T lymphocytes
LG Guidotti, T Ishikawa, MV Hobbs, B Matzke, R Schreiber, FV Chisari
Immunity 4 (1), 25-36, 1996
Cytokine signaling in 2002: new surprises in the Jak/Stat pathway
JJ O'Shea, M Gadina, RD Schreiber
Cell 109 (2), S121-S131, 2002
The IFNγ receptor: a paradigm for cytokine receptor signaling
EA Bach, M Aguet, RD Schreiber
Annual review of immunology 15 (1), 563-591, 1997
Adaptive immunity maintains occult cancer in an equilibrium state
CM Koebel, W Vermi, JB Swann, N Zerafa, SJ Rodig, LJ Old, MJ Smyth, ...
Nature 450 (7171), 903, 2007
Interferon-gamma: the major mediator of resistance against Toxoplasma gondii
Y Suzuki, MA Orellana, RD Schreiber, JS Remington
Science 240 (4851), 516-518, 1988
Batf3 deficiency reveals a critical role for CD8α+ dendritic cells in cytotoxic T cell immunity
K Hildner, BT Edelson, WE Purtha, M Diamond, H Matsushita, ...
Science 322 (5904), 1097-1100, 2008
Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens
MM Gubin, X Zhang, H Schuster, E Caron, JP Ward, T Noguchi, Y Ivanova, ...
Nature 515 (7528), 577, 2014
Das System kann den Vorgang jetzt nicht ausführen. Versuchen Sie es später erneut.
Artikel 1–20